ArticleFrontiers in pharmacology2026
Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous subtype of non-Hodgkin lymphoma. While R-CHOP improves prognosis, relapse persists in some patients. Jiedu Xiaoliu Formula (JDXLF), a traditional Chinese medicine (TCM) compound, may synergize with chemotherapy. This study aimed to evaluate the impact of JDXLF's on progression-free survival (PFS) and immune modulation in DLBCL. Methods: This retrospective cohort study included 188 patients diagnosed with DLBCL between January 2014 and December 2023 at Shanghai Municipal Hospital of Traditional Chinese Medicine. Patients were stratified into chemotherapy alone (n = 76), chemotherapy + JDXLF (n = 54), and post-chemotherapy JDXLF maintenance (n = 58). Kaplan-Meier survival, LASSO, and multivariate Cox regression were applied to evaluate progression-free survival (PFS) and prognostic factors. Secondary endpoints included overall response rate (ORR), TCM symptom scores, immune biomarkers, and adverse events. Results: Median PFS was significantly longer in the chemotherapy + JDXLF group (57 months) and JDXLF maintenance group (51 months) compared with chemotherapy alone (39 months; log-rank P < 0.05). Six-month, 1-year, and 2-year PFS rates were consistently higher in both JDXLF groups (all P < 0.05). Cox analysis confirmed that concurrent JDXLF independently reduced the risk of progression (HR = 0.54; 95% CI: 0.30-0.95; P = 0.031). ORR improved with JDXLF (85.2% vs. 76.4% with chemotherapy alone). At 24 months, JDXLF groups showed significantly lower TCM symptom scores (median 5-7 vs. 10; P < 0.001) and reduced monocytic myeloid-derived suppressor cell (M-MDSC) levels (0.08-0.09 vs. 0.15; P < 0.001). Conclusion: Jiedu Xiaoliu Formula combined with chemotherapy may improve progression-free survival and reduced immunosuppressive M-MDSC levels in DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.